Literature DB >> 32393592

Cytokine storm and the prospects for immunotherapy with COVID-19.

Leonard H Calabrese1.   

Abstract

Knowledge about the pathobiology of SARS-CoV-2 as it interacts with immune defenses is limited. SARS-CoV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 2 or 3 stages: most patients who recover experience 2 stages of illness commencing with an asymptomatic or paucisymptomatic incubation period, followed by a nonsevere symptomatic illness lasting for several weeks, occurring in about 80% of those infected. In the remainder, a third phase marked by a severe respiratory illness, often accompanied by multisystem dysfunction, coagulopathy, and shock is observed. This phase of the illness is characterized by hypercytokinemic inflammation and is often referred to as "cytokine storm." While the immunopathogenesis remains unclear, prospects of treating this severe phase of the illness with immunotherapy are evolving, with some treatments showing promise.
Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32393592     DOI: 10.3949/ccjm.87a.ccc008

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  19 in total

Review 1.  Neutrophil Extracellular Traps (NETs) in Severe SARS-CoV-2 Lung Disease.

Authors:  Monika Szturmowicz; Urszula Demkow
Journal:  Int J Mol Sci       Date:  2021-08-17       Impact factor: 5.923

2.  COVID-19 and the Heart: Could Transient Takotsubo Cardiomyopathy Be Related to the Pandemic by Incidence and Mechanisms?

Authors:  Paolo Angelini; Alexander Postalian; Eduardo Hernandez-Vila; Carlo Uribe; Briana Costello
Journal:  Front Cardiovasc Med       Date:  2022-06-27

3.  Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients.

Authors:  Stefania Croci; Martina Bonacini; Giovanni Dolci; Marco Massari; Nicola Facciolongo; Elisa Pignatti; Alessandra Pisciotta; Gianluca Carnevale; Aurelio Negro; Giulia Cassone; Francesco Muratore; Lucia Belloni; Alessandro Zerbini; Carlo Salvarani
Journal:  Front Cell Dev Biol       Date:  2021-02-05

Review 4.  Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.

Authors:  Seyed Hootan Hamidi; Sandhya Kadamboor Veethil; Seyedeh Harir Hamidi
Journal:  Pharmacol Rep       Date:  2021-04-21       Impact factor: 3.919

5.  The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?

Authors:  N Winchester; C Calabrese; L H Calabrese
Journal:  Pathog Immun       Date:  2021-03-08

Review 6.  An overview of some potential immunotherapeutic options against COVID-19.

Authors:  Maryam Bayat; Yahya Asemani; Mohammad Reza Mohammadi; Mahsa Sanaei; Mozhdeh Namvarpour; Reyhaneh Eftekhari
Journal:  Int Immunopharmacol       Date:  2021-02-26       Impact factor: 5.714

Review 7.  COVID-19 and myocarditis: a systematic review and overview of current challenges.

Authors:  Teresa Castiello; Georgios Georgiopoulos; Gherardo Finocchiaro; Monaco Claudia; Andrea Gianatti; Dimitrios Delialis; Alberto Aimo; Sanjay Prasad
Journal:  Heart Fail Rev       Date:  2021-03-24       Impact factor: 4.214

8.  Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.

Authors:  Edward L G Pryzdial; Edward M Conway; Alexander Leatherdale; Sophie Stukas; Victor Lei; Henry E West; Christopher J Campbell; Ryan L Hoiland; Jennifer Cooper; Cheryl L Wellington; Mypinder S Sekhon
Journal:  Med Microbiol Immunol       Date:  2022-01-16       Impact factor: 4.148

Review 9.  Is the COVID-19 thrombotic catastrophe complement-connected?

Authors:  Edward M Conway; Edward L G Pryzdial
Journal:  J Thromb Haemost       Date:  2020-09-18       Impact factor: 16.036

Review 10.  Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review.

Authors:  Yadong Fan; Ying Wang; Shuang Yu; Jun Chang; Yiqi Yan; Yiyang Wang; Yuhong Bian
Journal:  Chin Med       Date:  2021-07-28       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.